BackgroundÌý
Bipolar disorder (BD) has substantial morbidity and incompletely understood
neurobiological underpinnings.
ObjectiveÌý
To investigate brain chemistry in medication-free individuals with BD.
DesignÌý
Two-dimensional proton echo-planar spectroscopic imaging (PEPSI) (32
× 32, 1-cm3 voxel matrix) acquired axially through the cingulate
gyrus was used to quantify regional brain chemistry.
SettingÌý
The Center for Anxiety and Depression at the University of Washington
in Seattle and the Bipolar Research Programs at McLean Hospital and the Massachusetts
General Hospital in Boston.
ParticipantsÌý
Thirty-two medication-free outpatients with a diagnosis of BD type I
(BDI) or BD type II (BDII), predominantly in a depressed or mixed-mood state,
were compared with 26 age- and sex-matched healthy controls.
Main Outcome MeasuresÌý
Tissue type (white and gray) and regional analyses were performed to
evaluate distribution of lactate; glutamate, glutamine, and γ-aminobutyric
acid (Glx); creatine and phosphocreatine (Cre); choline-containing compounds
(Cho); N-acetyl aspartate; and myo-inositol. Chemical relationships for diagnosis and mood state were
evaluated.
ResultsÌý
Patients with BD exhibited elevated gray matter lactate (P = .005) and Glx (P = .007) levels; other
gray and white matter chemical measures were not significantly different between
diagnostic groups. Isolated regional chemical alterations were found. An inverse
correlation between 17-item Hamilton Depression Rating Scale scores and white
matter Cre levels was observed for BD patients.
ConclusionsÌý
Gray matter lactate and Glx elevations in medication-free BD patients
suggest a shift in energy redox state from oxidative phosphorylation toward
glycolysis. The possibility of mitochondrial alterations underlying these
findings is discussed and may provide a theoretical framework for future targeted
treatment interventions.
Bipolar disorder (BD) is a psychiatric disorder characterized by mooddisturbances with recurrent episodes of mania, hypomania, and depression.1 Bipolar disorder can be differentiated into clinicalsubtypes of BD type I (BDI), characterized by at least 1 episode of pure mania,and BD type II (BDII), characterized by less clinically severe hypomania andmajor depressive episodes.2,3 Thereis an approximately 1% prevalence rate for BDI among the adult population;the prevalence rate may be somewhat higher for BDII.4,5 Neurobiologicalmechanisms are thought to underlie BD, and there is evidence of a familial,and presumably genetic, predisposition for the disorder.6
Serendipitous observations of the mood-stabilizing effect of lithiumsalts and later certain anticonvulsants, such as valproic acid, have substantiallyimproved the prognosis of patients with BD. Despite this progress, these medicationsare not universally effective, and many individuals are unable to toleratetreatment-related adverse effects.6,7 Inaddition to incomplete clinical response, relapse and recurrence remain commonclinical problems.8,9 A recentsurvey of BD lifetime financial burden in the United States found associatedcosts to be up to $625Ìý000 per patient, depending on treatment refractorinessand chronicity of symptoms.10 Bipolar disordercontinues to be associated with substantial morbidity and mortality, rankingworldwide among psychiatric disorders behind only unipolar depression andalcohol abuse for related disabilities and overall economic load of the illness.11,12
Research conducted over several decades investigating biomarkers relatedto BD provides evidence for widespread alterations of multiple neurotransmitteror signal induction systems and physiological processes associated with thedisorder, as reviewed by Manji and Lenox.13 Increasingly,imaging techniques are being applied to better establish brain mechanismsunderlying the etiology of BD. Positron emission tomography studies, usedto characterize patterns of regional metabolism or cerebral blood flow inmood disorders, typically find regional or widely distributed abnormalitiesof reduced blood flow and metabolism in association with depressed mood states,including BD-related depression.14-17 Magneticresonance (MR) imaging studies, as reviewed by Strakowski et al,18 variablyfind evidence of reduced regional gray matter volumes associated with BD.16,19-23 Differingsubcortical patterns of structural abnormalities may occur across the spectrumof affective disorders; for example, basal ganglia and amygdalar enlargementare observed in BD,19,24 whereasvolumes of these structures may be reduced in unipolar depression.25,26 Similarly, neuroanatomic findingshave been reported to distinguish BD clinical subtypes, such as the observationof lateral ventricular enlargement in BDI but not BDII patients.27
Magnetic resonance spectroscopy, an imaging modality related to MR imaging,provides an in vivo tissue-based measure of brain chemistry using clinicalMR image scanners that is safe, noninvasive, and reproducible.28,29 Forneuropsychiatric applications at 1.5 T, as reviewed elsewhere,30-32 hydrogenH1 (1H) MR spectroscopy can detect and identify subtle alterationsin brain chemical composition, despite normal-appearing structure, throughquantifying the resonance frequency of certain 1H-containing chemicalcompounds that include the combined resonances of creatine and phosphocreatine(Cre); choline-containing compounds (Cho); N-acetylmoieties predominately composed of N-acetyl aspartate(NAA); myo-inositol (mI), which also contains somecontribution from scyllo-inositol at 1.5 T; the overlapping resonances ofglutamine, glutamate, and γ-aminobutyric acid (Glx); and lactate. Thedevelopment of rapid MR spectroscopy techniques, such as proton echo-planarspectroscopic imaging (PEPSI), allows fast, clinically feasible acquisitionof 2-dimensional images of brain chemical composition.33 Short-echotime (TE) measurements (eg, 20 milliseconds) can be acquired using PEPSI thatprovide a more accurate appraisal of brain chemical concentration, particularlyas some disease states, such as autism, can alter tissue relaxation characteristicsand substantially affect spectral quantification at longer TEs.34
The purpose of this study was to characterize brain chemical compositionin medication-free BD patients compared with age- and sex-matched healthycontrols (HCs). To ensure adequate numbers of medication-free participants,a dual-site study was conducted between Boston, Mass, and Seattle, Wash. Medication-freeBD patients were studied, because prior work35-41 suggestssecondary effects of mood stabilizers or antidepressants on MR spectroscopy–detectablechemicals and gray matter volume that could confound interpretation of findings.We evaluated diagnostic relationships for chemicals detectable by 1H-MRspectroscopy, including Cho, Cre, mI, Glx, and NAA, to extend prior work thatfound metabolic alterations in mood disorders. The present investigation furthersought to exploit the within-subject multiple voxel sampling acquired withPEPSI to evaluate whether lactate, a potential indicator of redox status butwith a low signal-to-noise ratio in the resting state, was altered in BD.To assess tissue-type specificity for chemical findings, gray and white mattercompartments were evaluated separately using established regression methods.42-44 We report tissue-specificand regional brain chemical findings in BD patients vs HCs, relationshipsto mood state, and clinical subtypes of BDI and BDII.
Participants were 32 adults with BD (14 men, 18 women; mean ±SD age, 30.3 ± 10.8 years) and 26 HCs (12 men, 14 women; mean ±SD age, 31.9 ± 7.7 years). Participants were recruited through theBipolar Research Programs at McLean Hospital and the Massachusetts GeneralHospital (BD patients = 15; HCs = 16) or the University of Washington Centerfor Anxiety and Depression (BD patients = 17; HCs = 10). Written, informedconsent, approved by either McLean Hospital and Massachusetts General Hospital,Harvard University, or the University of Washington Human Subjects ReviewBoards, was obtained from each participant before study enrollment. All participantstolerated the scanning procedure, but 3 BD patients (1 man, 2 women) and 2HCs (2 men) had invalid studies due to technical acquisition problems or movementartifacts and were not included in the statistical analyses. Additionally,only long-echo MR spectroscopy data (lactate) were acquired for 1 BD patient.There were no significant differences in sex distribution (χ21 = 0.11, P = .75) or age (t51 = 0.73, P = .47) between diagnosticgroups.
Psychiatric diagnosis was established through a ¶Ù³§²Ñ-±õ³Õ–based structured psychiatric interview by skilled clinicians (D.L.D.,C.D., A.L.S.). These clinicians also established diagnostic agreement betweensites before study inception and consensus for individual subject inclusionthroughout the study. The BD patients did not meet other DSM-IV Axis I diagnoses, including lifetime alcohol and/or other drugdependency or abuse within 6 months of study entrance. All participants weremedication free for 8 weeks or longer before the study. Participants wereoutpatients seeking treatment and had not stopped treatment to participatein the study. Of the 29 BD patients with valid studies, 26 had never beentreated with mood-stabilizing medications, and the 3 previously treated BDpatients (2 taking lithium and 1 taking valproic acid) had not been takingmood stabilizers for at least 1 year. Twelve BD patients, including the 3previously taking mood stabilizers, had been prescribed antidepressants inthe past but had not been taking them for at least 8 weeks or longer beforethe study. No patients had previously been treated with antipsychotic medication.The results of urine toxicology screening obtained before the study were negativefor psychoactive substances. Evidence of clinically significant medical problemsthrough medical history, laboratory workup, including thyroid studies, andphysical examination that evaluated for cerebral vascular disease, pulmonarydisease, endocrine disorders, severe sensory or motor impairments (deaf orblind), documented head trauma, or metal implants was exclusionary for participation.Healthy controls had no current symptoms or medical history consistent witha DSM-IV Axis I diagnosis, and there was no historyof clinically significant psychiatric disorders in their first-degree relatives.
Subtype classification of BD patients into BDI (n = 11; 5 men, 6 women;mean ± SD age, 31.9 ± 6.1 years) or BDII (n = 17; 7 men, 10women; mean ± SD age, 28.9 ± 10.5 years) was determined at studyentrance by structured psychiatric interview. One participant was not classifiedand excluded from further analysis. Mood state before MR imaging or MR spectroscopywas assessed using the 17-item Hamilton Depression Rating Scale (HAM-D)45 and the Young Mania Rating Scale (YMRS).46 The mean ± SD HAM-D score for the BD patientswas 17.7 ± 8.6 (BDI, 20.0 ± 8.2; BDII, 16.1 ± 9.0) comparedwith 1.2 ± 1.1 for the HCs. The mean ± SD YMRS score for theBD patients was 6.5 ± 7.7 (BDI, 9.7 ± 9.1; BDII, 4.6 ±6.4) compared with 0.3 ± 0.5 for HCs. The BD patients had an averageillness duration of 13.5 ± 10.2 years (range, 0.5-33.0 years), with13.6 ± 18.1 depressive episodes and 7.3 ± 7.6 hypomanic manicepisodes.
Mr imaging and mr spectroscopy acquisition
The PEPSI studies were performed using clinical 1.5-T SIGNA whole-bodyscanners (GE Medical Systems, Milwaukee, Wis), both equipped with version5.8 Genesis operating software. Experimental receive-only linear birdcagecoils, designed and built at the University of Washington, that provided approximately√√2 enhanced signal-to-noise ratio and improved coil homogeneityover conventional quadrature head coils (Cecil Hayes, PhD, unpublished data,1996) were used at both sites. The coil design incorporates a built-in headholder to minimize head motion during scanning.
Axial proton density and T2-weighted MR images were used for anatomiclocalization and tissue segmentation (TE, 13/91 milliseconds; repetition time[TR], 2000 milliseconds; field of view (FOV), 22 cm; matrix, 256 × 160;slice thickness, 3 mm). For PEPSI studies, anatomic volumes were acquiredfrom an axial section centered on the anterior cingulate (Figure 1). The PEPSI pulse sequence has been described in detailelsewhere.33,47 Two TEs and standardparameters were used for data acquisition (TE, 20/272 milliseconds; TR, 2000milliseconds; spatial matrix, 32 × 32; nominal voxel size, 1 cm3; FOV, 22 cm; slice thickness, 20 mm). Magnetic resonance spectroscopydata were acquired in scan blocks (20-millisecond chemical image: 4 numbersof excitation/[NEX]; 4-minute scan time; 272-millisecond chemical image: 8NEX; 8-minute scan time; 20-millisecond water image: 2 NEX; 2-minute scantime), totaling approximately 20 minutes, including shimming and scan setup.A full echo was collected for 20-millisecond chemical data and a partial echofor 272-millisecond chemical data, the latter necessitating a magnitude calculation(√[real2 + imaginary2]) for data reconstruction.47 Unsuppressed short-echo water scans were also collectedfrom the identical axial slice location (TE, 20 milliseconds; TR, 2000 milliseconds)for referencing both metabolite scans as previously described.34
The PEPSI chemical images were analyzed using software developed atthe University of Washington that used the LCModel package for spectral fitting48 (Figure 1).Consistent with our prior work to optimize LCModel parameters34 andto standardize measurements between sites, phantoms with known concentrationsof brain chemicals were prepared at McLean Hospital and scanned at variousacquisition parameters, and basis sets were created as detailed in the LCModelmanual. All data sets were analyzed unbiased by user interaction on workstations(SGI Octane; Silicon Graphics Inc, Mountain View, Calif) running IRIX system6.5.8.
To calculate chemical concentrations and relaxation estimates, LCModelwater amplitudes were adjusted by water molarity estimates and attenuationconstants were then multiplied by the partial volume tissue fraction. Chemicalamplitude maps were adjusted for the differential relaxation between in vitro(phantoms) and in vivo estimates for Cre, Cho, and NAA, which served to scalechemical output similar to our previous work.34 Metaboliteswere then multiplied by the inverted partial-volume–corrected waterterm to yield chemical concentration.49
Absolute T2 calculations from the short- and long-echo PEPSI data couldnot be accurately determined, because long-echo data were acquired as a partialecho, requiring a magnitude calculation for reconstruction. Thus, a relativemeasure of T2 relaxation (T2r) for each region was calculated from chemicalsmeasured at both short and long TEs (Cre, Cho, and NAA), as previously described.34
Because short-echo data afford the least biased estimation of chemicalconcentration, long-echo data were used only for lactate measurements andT2 relaxation time calculations.28,34,47 Chemicalmeasures from each spectral array were determined from all valid voxels foreach individual participant to achieve maximum signal-to-noise ratios. Thenumber of valid voxels from the 32 × 32 spectra array acquired per subjectwas not significantly different comparing BD and HC groups for all chemicalmeasurements (t<0.86 and P>.38for all).
Dual-echo axial images were skull stripped and then segmented usingmultispectral analytic tools within an image manipulation and visualizationpackage (Analyze; Mayo Clinic, Rochester, Minn). Specifically, sample regionsof gray matter, white matter, and cerebrospinal fluid (CSF) (eg, intraventricularCSF) were manually selected by a single rater (I.K.L.) blinded to patientdiagnosis. These pure exemplars, unbiased by partial volume, were used asstarting points for gaussian classification. Following segmentation, a secondscript written in MATLAB, a computer language used for array computation andvisualization, was used to offset the images to magnet center using MR imageheader coordinates and extract images within the PEPSI volume. Because PEPSIdata sets are acquired at magnet center, aligning anatomic images in thisway results in accurate registration.
The CSF and tissue maps were processed as previously detailed,34,50 including summation of images withinthe PEPSI volume, spatial filtering, and array reduction to match the chemicalarray spatial resolution (32 × 32). On a voxel-by-voxel basis, CSF datawere used for partial volume correction of metabolite quantification. Partialvolume tissue estimates of the PEPSI slab were similar between groups (BDpatients, 0.95 ± 0.02; HCs, 0.96 ± 0.01; t50 = 0.62; P = .54). For regressionanalyses, white and gray matter maps were used. The percentage of gray mattercomprising the axial slab studied using PEPSI was also similar between groups(BD patients, 52.96% ± 4.71%; HCs, 51.78% ± 4.98%; t50 = .88; P = .38). For each participant,using all valid spectroscopy voxels, regression analyses were performed comparingthe fractional tissue volume (percentage of gray or white matter per voxel)to concentration and relaxation values. This approach, similar to that usedby other investigators,42-44 takesadvantage of the large number of voxel samples obtained using spectroscopicimaging to calculate estimates of pure tissue neurochemistry (regression intercepts)and the relationship between tissue classes (regression slope). Characteristicchemical regression plots from an individual BD patient are shown in Figure 2.
Region-of-interest analyses
For region-of-interest (ROI) selection, the PEPSI voxel grid (32 ×32 matrix) was graphically overlaid onto the axial MR image data set for selectinganatomic loci: frontal white matter left and right, cingulate left and right,caudate left and right, putamen left and right, thalamus left and right, insulaleft and right, parietal white matter left and right, and midline occiput(Figure 3). A rater (S.D.F.) blindedto patient diagnosis recorded the voxel position for each ROI into a texttemplate, and a MATLAB script was used to extract concentration data by regioninto a tabulated text file. For nuclei, the voxel chosen was centered on theanatomic target structure; if no corresponding voxel could be selected, amissing value was entered. In other larger anatomic regions, ROIs were averagedacross contiguous voxels to maximize signal-to-noise ratio.
Stepwise multivariate linear regression using SPSS statistical softwareversion 11 (SPSS Inc, Chicago, Ill) assessed interrelationships between categoricalvariables of psychiatric diagnosis and clinical subtype diagnosis with continuouspredictor variables of chemical concentrations (20 milliseconds for Cho, Cre,NAA, mI, and Glx; 272 milliseconds for lactate). Chemical T2r (Cho, Cre, andNAA) was separately modeled. Regional chemical composition by diagnosis wasevaluated using independent t tests. For BD patients,mood state rating scales in relationship to chemical measures were evaluatedusing the Pearson r. Significance was fixed at a2-tailed α of .05. Bonferroni correction for ROI analyses was appliedby dividing the α level by number of regions assessed (adjusted α= .003) and for mood assessment by number of gray-white chemical measures(adjusted α = .004). Values are presented as mean ± SD. Regionaland diagnostic subgroup analyses by mood were not performed because of powerconsiderations.
Brain chemical concentrations by tissue type are given for each diagnosticgroup in Table 1. A significantmodel observed for gray matter chemical measures and diagnosis (BD patientsvs HCs) (F2,51 = 8.34, P = .001) was bestpredicted by elevated lactate (19.75% increase, β = .37, t = 2.96, P = .005) and Glx levels (10.01%increase, β = .35, t = 2.83, P = .007) in BD patients; other gray matter chemicals were nonsignificantwithin the model (β<.28, t≤1.07, P ≥.32 for all). The model for white matter chemicalsand diagnosis did not reach statistical significance (F1,51 = 3.61, P = .06). The models for diagnosis and gray matter T2r(F1,51 = 1.06, P = .31) or white matterT2r (F1,51 = 3.59, P = .07) also did notreach statistical significance. Similarly, the models for diagnosis and chemicalregression slopes (F1,51 = 3.12, P = .08)(Table 1) or T2r regression slopes(F1,51 = 0.30, P = .59) did not reachstatistical significance.
Brain chemical ROI relationships were assessed (Figure 3). Chemical alterations included increased Glx levels inthe left cingulate (t39 = 2.09, P = .04) and increased Cho levels in the left caudate (t37 = 2.71, P = .01)in BD patients. The BD group also exhibited increased Cho levels in the rightputamen (t50 = 2.43, P = .02), increased NAA levels in the left putamen (t52 = 3.57, P = .001), and increasedGlx levels in the left insula (t51 = 3.32, P = .002). After Bonferroni correction for the multipleregions compared (adjusted α = .003), only putamen and insula findingsremained statistically significant.
The BD patients differentiated into BDI and BDII clinical subtypes werefurther evaluated for gray and white matter chemical differences (Table 2). Comparing BDI patients and HCs,a significant model for gray matter chemicals (F1,33 = 12.24, P = .001) was predicted by elevated lactate levels in theBDI subgroup (31.45% increase, β = .53, t =3.50, P = .001); other gray matter chemicals didnot significantly contribute to the model (β<.19, t≤1.25, P≥.22 for all). No significantmodel for white matter chemicals and BDI vs HC diagnosis was found (F1,33 = 0.59, P = .74). There were also no statisticallysignificant models for gray or white matter T2r and diagnosis (F<1.23, P>.27 for all). Modeling chemical regression slopes, asignificant model (F1,33 = 6.39, P = .02)was predicted by an increased lactate white-gray regression slope in BDI patients(0.06 ± 0.50 vs −0.35 ± 0.51, β = .41, t = 2.53, P = .02).
Comparing BDII patients and HCs, a statistically significant model forgray matter chemicals (F2,40 = 7.13, P =.002) was predicted by elevated Glx levels (13.97% increase, β = .47, t = 3.29, P = .002) and trendelevated lactate levels (11.3% increase, β = .24, t = 1.70, P = .10) in the BDII subgroup; othergray matter chemicals did not contribute to the model (β<.11, t≤0.69, P>.49 for all). A significantmodel for BDII compared with HCs for white matter chemicals (F1,40 =5.47, P = .03) was predicted by elevated Glx levelsin the BDII subgroup (11.6% increase, β = .35, t =2.34, P = .03); other white matter chemicals didnot contribute to the model (β<.23, t<1.39, P>.17 for all). Additionally, significant models observedfor gray matter T2r (F1,40 = 5.27, P =.03) were predicted by shortened Cho T2r (decreased 15.1% from HCs, β= .35, t = 2.30, P = .03)and white matter T2r (F1,40 = 4.13, P =.05) predicted by shortened Cho T2r (decreased 9.9% from HCs, β= .31, t = 2.03, P = .05)in BDII patients. The model for white-gray regression slope and BDII vs HCdiagnosis did not reach statistical significance (F1,40 = 3.21, P = .08).
Clinical mood state of BD patients at time of scanning was evaluatedin relationship to averaged gray-white matter chemical measures using thePearson r. An inverse correlation with HAM-D scoreswas found for white matter Cre (r28 =−0.55, P = .003); no significant interactionswere observed between HAM-D scores and other gray or white matter chemicals(r<.33, P>.09). The YMRSscores were inversely correlated with mI levels both in gray matter (r28 = −0.46, P =.01) and white matter (r28 = −0.42, P = .03); no significant relationships were observed forother gray or white matter chemicals (r<.36, P≥.06). After Bonferroni correction for the number ofgray and white matter chemical measures (adjusted α = .004), a significantinteraction between white matter Cre and HAM-D scores remained (Figure 4).
Medication-free BD patients demonstrated elevated lactate and Glx levelsin gray matter compared with the HC group; other gray-white matter chemicalconcentrations, chemical T2r measures, and chemical regression slopes betweenwhite and gray matter were not significantly different between groups. TheBDI patients demonstrated elevated gray matter lactate and altered lactatetissue distribution that was shifted toward gray matter compared with HCs;the BDII patients exhibited elevated Glx and trend elevated lactate levelsin gray matter, as well as elevated white matter Glx levels. The BDII patientsadditionally demonstrated shortening of Cho T2r in both gray and white matter.Chemical differences for BDI and BDII patients may reflect intrinsic diagnosticdifferences or illness severity, because BDI patients had higher HAM-D andYMRS scores. A significant inverse correlation also was found for white matterCre and HAM-D scores in BD patients. We believe that this is the first reportof elevated gray matter lactate levels in BD. Several recent single-voxel 1H-MR spectroscopy studies of BD also have reported elevated Glx levels.51,52 Lactate levels in those studies werenot reported because of characteristics of the acquisition parameters andsignal-to-noise ratio considerations.
Although our line-fitting analyses fit the separate components of Glx,we did not report individual values because of the substantial overlap ofthese multiplets at 1.5 T. Thus, we cannot identify what component of Glxwas elevated in BD patients. However, findings of decreased Glx measured inthe anterior cingulate cortex of medicated major depressive disorder patientshave been suggested to primarily reflect lowered glutamate levels.53 Future investigation using higher-field scannersmay improve deconvolution of the Glx spectral peaks and better address limitationsof spectral resolution at 1.5 T.
Other brain chemicals and T2r measures in both gray and white matterwere not significantly different between diagnostic groups. White-gray regressionslopes for chemical distributions between tissues are compatible with priorwork42-44 anddid not differentiate diagnostic groups, although BDI patients demonstratedan increased slope for lactate distribution between white and gray matter.Regional findings, although somewhat overlapping with the anatomic distributionfound in previous work,38,53-56 shouldbe interpreted conservatively. Further studies would be necessary to confirmregional Glx and NAA elevations observed in this BD sample.
Investigations of mood disorders using single-voxel 1H-MRspectroscopy have largely tested hypotheses of Cho alterations wherein bothregional elevations39,56,57 anddecreased Cho levels38,40,58 havebeen reported in association with depressed mood state. In our study, tissue-specificCho levels were not found to be altered in relationship to either BD diagnosisor mood state. We also did not find evidence of tissue-specific or regionalNAA reductions that have been reported in association with BD and perhapsmore specifically with psychosis.52,59-61 Variablefindings reported in the literature may reflect differences in clinical populations,medication status, brain regions studied, or MR spectroscopy acquisition parametersthat, in the setting of disease state–related T2 changes, as found forCho in this study, could substantially influence chemical concentration estimates.
In this study, mood-related findings of an inverse correlation for whitematter Cre with HAM-D scores are comparable with prior work that found decreasedphosphocreatine/Cre levels in association with depression.62,63 Inthis sample, the predominantly depressed or mixed-mood state of the BD patientslimits any relationship being identified between manic symptoms and chemicalalterations. A growing MR spectroscopy literature supports the presence ofbrain metabolic alterations in BD with variable relationships to mood state.Initial MR spectroscopy studies of BD used phosphorus P31 (31P)–labeledMR spectroscopy to evaluate brain energy and phospholipid metabolism.37 A meta-analysis of 8 31P-MR spectroscopystudies provides support for state-specific alterations of phospholipid membranesand high-energy phosphates in BD that primarily reflect increased phosphomonoesterlevels and decreased phosphocreatinine levels in the depressed state.54 Decreased phosphomonoester levels also have beenobserved in euthymic BDI patients, although not BDII patients, compared withHCs.62 More generally, findings of decreased βand total nucleotide triphosphate (primarily composed of adenosine triphosphate)provide evidence for abnormal brain energy metabolism in mood disorders.55,64 Because brain intracellular pH determinedby 31P-MR spectroscopy is found to be decreased in medication-freeBD patients in both manic and depressed mood states, as well as in euthymicBD patients stabilized with lithium treatment, metabolic aberrations may beintrinsic to the underlying pathophysiology of BD.65,66 Findingsof decreased frontal lobe intracellular pH in BD patients,65 consistentwith lactate acidosis, are postulated by those investigators to reflect underlyingmitochondrial dysfunction.66
It is possible that lactate elevations observed in this study couldreflect nonspecific manifestations of state-dependent anxiety, although participantsin our study did not report anxiety or any particular discomfort with beingin the scanner. Despite substantial baseline anxiety, we also do not typicallyobserve elevated baseline lactate levels in patients with panic disorder aboutto undergo a lactate infusion designed to induce panic.47,50,67,68 However,the diagnostic specificity of lactate and Glx findings remains uncertain.In a study using essentially the same methods, we observed no alterationsin either lactate or Glx in young children with autism.34 Onthe other hand, elevated lactate levels have also recently been found in associationwith first-break psychosis.69
Our findings of elevated gray matter lactate levels in the BD patientssuggest a shift in redox state from oxidative toward glycolytic energy utilization.Although its role in brain metabolism and homeostasis remains unresolved,70,71 earlier considerations of lactatebeing solely the by-product of anaerobic metabolism have been substantiallymodified by more recent work suggesting an important role for lactate in brainbioenergetics.72-74 Normalneuronal activation requires that some fraction of the energy expended comesfrom glycolysis. During rapid neuronal firing, coupled to increased extracellularglutamate levels, approximately one third of energy expenditure is estimatedto be contributed via glycolysis and increased lactate production.75 It is conceivable that increased or more sustainedrapid neuronal firing, possibly reflecting neuroexcitatory effects of increasedextracellular glutamate, with a resultant increased fraction of energy utilizationvia glycolysis, could explain the elevated gray matter lactate levels observedin BD patients. Because hypoperfusion is among the more consistent brain metabolicalterations found in BD,14,15,17 thisfactor could also contribute to, or account for, a shift in redox state towardglycolysis. Alternatively, or in conjunction with these considerations, recentin vivo evidence supports an association between elevated brain lactate andGlx levels and cyanide-induced inhibition of mitochondrial oxidative metabolism;mechanisms underlying brain glutamate increases are postulated to reflectalterations in the release and reuptake of glutamate that are dependent onintact oxidative metabolism.76
Elevated brain lactate is considered to be a sensitive marker for mitochondrialcompromise,77 but severe clinical manifestations(eg, MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke]syndrome) also are variably associated with reduced NAA levels.78 Althoughwe did not find evidence for reduced NAA in BD patients, this might reflectthe lesser severity of mitochondrial compromise speculated to account forlactate and Glx level elevations observed in our sample. The spectrum of clinicaland metabolic manifestations of mitochondrial dysfunction may reflect variableloading of mitochondrial DNA polymorphisms, some possibly linked to BD,79 that exhibit differing threshold response to oxidativestress.80 Phospholipid membrane alterationsfound in association with BD may also interfere with mitochondrial function,just as mitochondrial dysfunction can alter phospholipid metabolism.81-84
Considerations regarding the possible role of mitochondrial compromisein BD have important treatment implications; for example, evidence of thepossible neuroprotective properties of lithium,35,36,41 alsoobserved under conditions of elevated glutamate levels or ischemia, are hypothesized,in part, to be mediated through bcl-2 elevation, a neuroprotective proteinthat also has mitochondrial membrane-stabilizing effects.85 Althoughthe demonstration of causal relationships remains challenging, the presentwork suggests subtle alterations of energy metabolism in BD.
To summarize, gray matter lactate and Glx level elevations in medication-freeBD patients suggest altered cellular energy metabolism. These chemical alterations,suggestive of a redox shift toward glycolysis, may reflect a generalized patternof compromised mitochondrial metabolism in BD.
Corresponding author and reprints: Stephen R. Dager, MD, Universityof Washington Neuroimaging Research Group and the Center for Anxiety and Depression,1100 NE 45th Street, Suite 555, Seattle, WA 98105 (e-mail: srd@u.washington.edu).
Submitted for publication March 10, 2003; final revision received December18, 2003; accepted January 18, 2004.
This study was supported in part by grant RO1 MH58681 from the NationalInstitute of Mental Health, Bethesda, Md, and the Poitras Foundation and theStanley Foundation Bipolar Disorders Research Center at McLean Hospital, Boston,Mass.
We thank Marie Domsalla, Chris Budech, and Carolyn Bea for assistancein recruiting participants and organizational assistance. We also thank DeniseEchelard, Gerald Ortiz, and James Anderson for MR technical support.
1.American Psychiatric Association,ÌýDiagnostic and Statistical Manual of Mental Disorders,Fourth Edition.Ìý Washington, DC American Psychiatric Association1994;
2.Dunner
ÌýDLÌýSubtypes of bipolar affective disorder with particular regard to bipolarII.ÌýÌýPsychiatr Dev. 1983;175-Ìý86
3.Dunner
ÌýDLÌýA review of the diagnostic status of "Bipolar II" for the DSM-IV workgroup on mood disorders.ÌýÌý¶Ù±ð±è°ù±ð²õ²õ¾±´Ç²Ô. 1993;12-Ìý10
4.Weissman
ÌýMMBland
ÌýRCCanino
ÌýGJFaravelli
ÌýCGreenwald
ÌýSHwu
ÌýHGJoyce
ÌýPRKaram
ÌýEGLee
ÌýCKLellouch
ÌýJLepine
ÌýJPNewman
ÌýSCRubio-Stipec
ÌýMWells
ÌýJEWickramaratne
ÌýPJWittchen
ÌýHYeh
ÌýEKÌýCross-national epidemiology of major depression and bipolar disorder.ÌýÌý´³´¡²Ñ´¡. 1996;276293-Ìý299
5.Bland
ÌýRCÌýEpidemiology of affective disorders: a review.ÌýÌýCan J Psychiatry. 1977;42367-Ìý377
6.Jamison
ÌýKRGoodwin
ÌýFKÌýManic Depressive Illness.Ìý New York, NY Oxford University Press1990;
7.Dunner
ÌýDLÌýOptimizing lithium treatment.ÌýÌýJ Clin Psychiatry. 2000;6176-Ìý81
8.Keck
ÌýPE
ÌýJrMcElroy
ÌýSLÌýOutcome in the pharmacologic treatment of bipolar disorder.ÌýÌýJ Clin Psychopharmacol. 1996;16
(2)
115S-Ìý23S
9.Bowden
ÌýCLÌýEfficacy of lithium in mania and maintenance therapy of bipolar disorder.ÌýÌýJ Clin Psychiatry. 2000;6135-Ìý40
10.Begley
ÌýCEAnnegers
ÌýJFSwann
ÌýACLewis
ÌýCCoan
ÌýSSchnapp
ÌýWBBryant-Comstock
ÌýLÌýThe lifetime cost of bipolar disorder in the US: an estimate for newcases in 1998.ÌýÌý±Ê³ó²¹°ù³¾²¹³¦´Ç±ð³¦´Ç²Ô´Ç³¾¾±³¦²õ. 2001;19483-Ìý495
11.Wyatt
ÌýRJHenter
ÌýIÌýAn economic evaluation of manic-depressive illness—1991.ÌýÌýSoc Psychiatry Psychiatr Epidemiol. 1995;30213-Ìý219
12.Murray
ÌýCJLLopez
ÌýADÌýThe Global Burden of Disease.Ìý Boston, Mass Harvard University Press1996;
13.Manji
ÌýHKLenox
ÌýRHÌýSignaling: cellular insights into the pathophysiology of bipolar disorder.ÌýÌýBiol Psychiatry. 2000;48518-Ìý530
14.Baxter
ÌýLRPhelps
ÌýMEMazziotta
ÌýJCSchwartz
ÌýJMGerner
ÌýRHSelin
ÌýCESumida
ÌýRMÌýCerebral metabolic rates for glucose in mood disorders: studies withpositron emission tomography and fluorodeoxyglucose F 18.ÌýÌýArch Gen Psychiatry. 1985;42441-Ìý447
15.Baxter
ÌýLRSchwartz
ÌýJMPhelps
ÌýMEMazziotta
ÌýJCGuze
ÌýBHSelin
ÌýCEGerner
ÌýRHSumida
ÌýRMÌýReduction of prefrontal cortex glucose metabolism common to three typesof depression.ÌýÌýArch Gen Psychiatry. 1989;46243-Ìý250
16.Drevets
ÌýWCPrice
ÌýJLSimpson
ÌýJRTodd
ÌýRDReich
ÌýTVannier
ÌýMRaichle
ÌýMEÌýSubgenual prefrontal cortex abnormalities in mood disorders.ÌýÌý±·²¹³Ù³Ü°ù±ð. 1997;386824-Ìý827
17.Ketter
ÌýTAKimbrell
ÌýTAGeorge
ÌýMSDunn
ÌýRTSpeer
ÌýAMBenson
ÌýBEWillis
ÌýMWDanielson
ÌýAFrye
ÌýMAHerscovitch
ÌýPPost
ÌýRMÌýEffects of mood and subtype on cerebral glucose metabolism in treatment-resistantbipolar disorder.ÌýÌýBiol Psychiatry. 2001;4997-Ìý109
18.Strakowski
ÌýSMAdler
ÌýCMDelBello
ÌýMPÌýVolumetric MRI studies of mood disorders: do they distinguish unipolarand bipolar disorder?ÌýÌýBipolar Disord. 2002;480-Ìý88
19.Strakowski
ÌýSMDelBello
ÌýMPSax
ÌýKWZimmerman
ÌýMEShear
ÌýPKHawkins
ÌýJMLarson
ÌýERÌýBrain magnetic resonance imaging of structural abnormalities in bipolardisorder.ÌýÌýArch Gen Psychiatry. 1999;56254-Ìý260
20.Zipursky
ÌýRBSeeman
ÌýMVBury
ÌýALangevin
ÌýRWortzman
ÌýGKatz
ÌýRÌýDeficits in gray matter volume are present in schizophrenia but notbipolar disorder.ÌýÌýSchizophr Res. 1997;2685-Ìý92
21.Lim
ÌýKORosenbloom
ÌýMJFaustman
ÌýWOSullivan
ÌýEVPfefferbaum
ÌýAÌýCortical gray matter deficit in patients with bipolar disorder.ÌýÌýSchizophr Res. 1999;40219-Ìý227
22.Lopez-Larson
ÌýMPDelBello
ÌýMPZimmerman
ÌýMESchwiers
ÌýMLStrakowski
ÌýSMÌýRegional prefrontal gray and white matter abnormalities in bipolardisorder.ÌýÌýBiol Psychiatry. 2002;5293-Ìý100
23.Lyoo
ÌýIKKim
ÌýJMStoll
ÌýALDemopulos
ÌýCParow
ÌýADager
ÌýSRFriedman
ÌýSDDunner
ÌýDLRenshaw
ÌýPFÌýFrontal lobe gray matter density decreases in bipolar disorders.ÌýÌýBiol Psychiatry. In press
24.Altshuler
ÌýLLBartzokis
ÌýGGrieder
ÌýTCurran
ÌýJJimenez
ÌýTLeight
ÌýKWilkins
ÌýJGerner
ÌýRMintz
ÌýJÌýAn MRI study of temporal lobe structures in men with bipolar disorderor schizophrenia.ÌýÌýBiol Psychiatry. 2000;48147-Ìý162
25.Drevets
ÌýWCVideen
ÌýTOPrice
ÌýJLPreskorn
ÌýSHCarmichael
ÌýSTRaichle
ÌýMEÌýA functional neuroanatomy of unipolar depression.ÌýÌýJ Neurosci. 1992;123628-Ìý3641
26.Sheline
ÌýYIGado
ÌýMHPrice
ÌýJLÌýAmygdala core nuclei volumes are decreased in recurrent major depression.ÌýÌý±·±ð³Ü°ù´Ç°ù±ð±è´Ç°ù³Ù. 1998;92023-Ìý2028
27.Hauser
ÌýPMatochik
ÌýJAltshuler
ÌýLLDenicoff
ÌýKDConrad
ÌýALi
ÌýXHauser
ÌýPMatochik
ÌýJÌýMRI-based measurements of temporal lobe and ventricular structuresin patients with bipolar I and bipolar II disorders.ÌýÌýJ Affect Disord. 2000;6025-Ìý32
28.Brooks
ÌýWMFriedman
ÌýSDStidley
ÌýCÌýReproducibility of 1H MRS in vivo..ÌýÌýMagn Reson Med. 1999;41193-Ìý197
29.Schirmer
ÌýTAuer
ÌýDPÌýOn the reliability of quantitative clinical magnetic resonance spectroscopyof the human brain.ÌýÌýNMR Biomed. 2000;1328-Ìý36
30.Dager
ÌýSRSteen
ÌýRGÌýApplications of MRS to the investigation of neuropsychiatric disorders.ÌýÌý±·±ð³Ü°ù´Ç±è²õ²â³¦³ó´Ç±è³ó²¹°ù³¾²¹³¦´Ç±ô´Ç²µ²â. 1992;6249-Ìý266
31.Soares
ÌýJCKrishnan
ÌýKRRKeshavan
ÌýMSÌýNuclear magnetic resonance spectroscopy: new insights into the pathophysiologyof mood disorders.ÌýÌý¶Ù±ð±è°ù±ð²õ²õ¾±´Ç²Ô. 1996;414-Ìý30
32.Lyoo
ÌýIKRenshaw
ÌýPFÌýMagnetic resonance spectroscopy: current and future applications inpsychiatric research.ÌýÌýBiol Psychiatry. 2002;51195-Ìý207
33.Posse
ÌýSDager
ÌýSRRichards
ÌýTLYuan
ÌýCArtru
ÌýAAOgg
ÌýRArtru
ÌýAAMuller-Gartner
ÌýHWHayes
ÌýCÌýIn vivo measurement of regional brain metabolicresponse to hyperventilation using functional proton echo-planar spectroscopicimaging (PEPSI).ÌýÌýMagn Reson Med. 1997;37858-Ìý865
34.Friedman
ÌýSDShaw
ÌýDWWArtru
ÌýAARichards
ÌýTLGardner
ÌýJDawson
ÌýGPosse
ÌýSDager
ÌýSRÌýRegional brain chemical alterations in young children with autism spectrumdisorder.ÌýÌý±·±ð³Ü°ù´Ç±ô´Ç²µ²â. 2003;60100-Ìý107
35.Moore
ÌýGJBebchuk
ÌýJMHasanat
ÌýKChen
ÌýGSeraji-Bozorgzad
ÌýNWilds
ÌýIBFaulk
ÌýMWKoch
ÌýSGlitz
ÌýDAJolkovsky
ÌýLManji
ÌýHKÌýLithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?ÌýÌýBiol Psychiatry. 2000;481-Ìý8
36.Moore
ÌýGJBebchuk
ÌýJMWilds
ÌýIBChen
ÌýGManji
ÌýHKMenji
ÌýHKÌýLithium-induced increase in human brain gray matter.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2000;3561241-Ìý1242
37.Kato
ÌýTShioiri
ÌýTTakahashi
ÌýSInubushi
ÌýTÌýMeasurement of brain phosphoinositide metabolism in bipolar patientsusing in vivo31P-MRS.ÌýÌýJ Affect Disord. 1991;22185-Ìý190
38.Renshaw
ÌýPFLafer
ÌýBBabb
ÌýSMFava
ÌýMStoll
ÌýALChristensen
ÌýJDMoore
ÌýCMYurgelun-Todd
ÌýDABonello
ÌýCMPillay
ÌýSSRothschild
ÌýAJNierenberg
ÌýAARosenbaum
ÌýJFCohen
ÌýBMÌýBasal ganglia choline levels in depression and response to fluoxetinetreatment: an in vivo proton magnetic resonance spectroscopystudy.ÌýÌýBiol Psychiatry. 1997;41837-Ìý843
39.Charles
ÌýHCLazeyras
ÌýFKrishnan
ÌýKRRBoyko
ÌýOBPayne
ÌýMMoore
ÌýDÌýBrain choline in depression: in vivo detectionof potential pharmacodynamic effects of antidepressant therapy using hydrogenlocalized spectroscopy.ÌýÌýProg Neuropsychopharmacol Biol Psychiatry. 1994;181121-Ìý1127
40.Sonawalla
ÌýSBRenshaw
ÌýPFMoore
ÌýCMAlpert
ÌýJENierenberg
ÌýAARosenbaum
ÌýJFFava
ÌýMÌýCompounds containing cytosolic choline in the basal ganglia: a potentialbiological marker of true drug response to fluoxetine.ÌýÌýAm J Psychiatry. 1999;1561638-Ìý1640
41.Sassi
ÌýRBNicoletti
ÌýMBrambilla
ÌýPMallinger
ÌýAGFrank
ÌýEKupfer
ÌýDJKeshavan
ÌýMSSoares
ÌýJCÌýIncreased gray matter volume in lithium-treated bipolar disorder patients.ÌýÌýNeurosci Lett. 2002;329243-Ìý245
42.Lim
ÌýKOSpielman
ÌýDMÌýEstimating NAA in cortical gray matter with applications for measuringchanges due to aging.ÌýÌýMagn Reson Med. 1997;37372-Ìý377
43.Doyle
ÌýTJBedell
ÌýBJNarayana
ÌýPAÌýRelative concentrations of proton MR visible neurochemicals in grayand white matter in human brain.ÌýÌýMagn Reson Med. 1995;33755-Ìý759
44.Pfefferbaum
ÌýAAdalsteinsson
ÌýESpielman
ÌýDSullivan
ÌýEVLim
ÌýKOÌýIn vivo spectroscopic quantification of theN-acetyl moiety, creatine, and choline from large volumes of brain gray andwhite matter: effects of normal aging.ÌýÌýMagn Reson Med. 1999;41276-Ìý284
45.Hamilton
ÌýMÌýA rating scale for depression.ÌýÌýJ Neurol Neurosurg Psychiatry. 1960;2356-Ìý62.
46.Young
ÌýRCBiggs
ÌýJTZiegler
ÌýVEMeyer
ÌýDAÌýA rating scale for mania: reliability, validity, and sensitivity.ÌýÌýBr J Psychiatry. 1978;133429-Ìý435
47.Dager
ÌýSRFriedman
ÌýSDHeide
ÌýALayton
ÌýMERichards
ÌýTLArtru
ÌýAAStrauss
ÌýWHayes
ÌýCPosse
ÌýSÌýTwo-dimensional proton echo-planar spectroscopic imaging (PEPSI) ofbrain metabolic changes during lactate-induced panic.ÌýÌýArch Gen Psychiatry. 1999;5670-Ìý77
48.Provencher
ÌýSWÌýEstimation of metabolite concentrations from localized in vivo proton NMR spectra.ÌýÌýMagn Reson Med. 1993;30672-Ìý679
49.Barker
ÌýPTSoher
ÌýBJBlackband
ÌýSJChatham
ÌýJCMathews
ÌýVPBryan
ÌýRNÌýQuantitation of proton NMR spectra of the human brain using tissuewater as an internal concentration reference.ÌýÌýNMR Biomed. 1993;689-Ìý94
50.Friedman
ÌýSDDager
ÌýSRRichards
ÌýTLPetropoulos
ÌýHPosse
ÌýSÌýModeling brain compartmental lactate response to metabolic challenge.ÌýÌýPsychiatry Res Neuroimaging. 2000;9855-Ìý66
51.Castillo
ÌýMKwock
ÌýLCourvoisie
ÌýHHooper
ÌýSRÌýProton MR spectroscopy in children with bipolar affective disorder:preliminary observations.ÌýÌýAJNR Am J Neuroradiol. 2000;21832-Ìý838
52.Cecil
ÌýKMDelBello
ÌýMPMorey
ÌýRStrakowski
ÌýSMÌýFrontal lobe differences in bipolar disorder as determined by protonMR spectroscopy.ÌýÌýBipolar Disord. 2002;4357-Ìý365
53.Auer
ÌýDPPütz
ÌýBKraft
ÌýELipinski
ÌýBSchill
ÌýJHolsboer
ÌýFÌýReduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study.ÌýÌýBiol Psychiatry. 2000;47305-Ìý313
54.Yildiz
ÌýASachs
ÌýGSDorer
ÌýDJRenshaw
ÌýPFÌý31P nuclear magnetic resonance spectroscopy findings inbipolar illness: a meta-analysis.ÌýÌýPsychiatry Res. 2001;106181-Ìý191
55.Moore
ÌýCMChristensen
ÌýJDLafer
ÌýBFava
ÌýMRenshaw
ÌýPFÌýLower levels of nucleoside triphosphate in the basal ganglia of depressedsubjects: a phosphorous-31 magnetic resonance spectroscopy study.ÌýÌýAm J Psychiatry. 1997;154116-Ìý118
56.Hamakawa
ÌýHKato
ÌýTMurashita
ÌýJKato
ÌýNÌýQuantitative proton magnetic resonance spectroscopy of the basal gangliain patients with affective disorders.ÌýÌýEur Arch Psychiatry Clin Neurosci. 1998;24853-Ìý58
57.Steingard
ÌýRJYurgelun-Todd
ÌýDAHennen
ÌýJMoore
ÌýJCMoore
ÌýCMVakili
ÌýKYoung
ÌýADKatic
ÌýABeardslee
ÌýWRRenshaw
ÌýPFÌýIncreased orbitofrontal cortex levels of choline in depressed adolescentsas detected by in vivo proton magnetic resonancespectroscopy.ÌýÌýBiol Psychiatry. 2000;481053-Ìý1061
58.Ende
ÌýGBraus
ÌýDFWalter
ÌýSWeber-Fahr
ÌýWHenn
ÌýFAÌýThe hippocampus in patients treated with electroconvulsive therapy:a proton magnetic resonance spectroscopic imaging study.ÌýÌýArch Gen Psychiatry. 2000;57937-Ìý943
59.Winsberg
ÌýMESachs
ÌýNTate
ÌýDLAdalsteinsson
ÌýESpielman
ÌýDKetter
ÌýTAÌýDecreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder.ÌýÌýBiol Psychiatry. 2000;47475-Ìý481
60.Deicken
ÌýRFPegues
ÌýMPAnzalone
ÌýSFeiwell
ÌýRSoher
ÌýBÌýLower concentration of hippocampal N-acetylaspartate in familial bipolarI disorder.ÌýÌýAm J Psychiatry. 2003;160873-Ìý882
61.Chang
ÌýKAdleman
ÌýNDienes
ÌýKBarnea-Goraly
ÌýNReiss
ÌýAKetter
ÌýTÌýDecreased N-acetylaspartate in children with familial bipolar disorder.ÌýÌýBiol Psychiatry. 2003;531059-Ìý1065
62.Kato
ÌýTTakahashi
ÌýSShioiri
ÌýTMurashita
ÌýJHamakawa
ÌýHInubushi
ÌýTÌýReduction of brain phosphocreatine in bipolar-II disorder detectedby phosphorous-31 magnetic resonance spectroscopy.ÌýÌýJ Affect Disord. 1994;31125-Ìý133
63.Hamakawa
ÌýHKato
ÌýTShioiri
ÌýTInubushi
ÌýTKato
ÌýNÌýQuantitative proton magnetic resonance spectroscopy of the bilateralfrontal lobes in patients with bipolar disorder.ÌýÌýPsychol Med. 1999;29639-Ìý644
64.Volz
ÌýHPRzanny
ÌýRRiehemann
ÌýSMay
ÌýSHegewald
ÌýHPreussler
ÌýBHubner
ÌýGKaiser
ÌýWASauer
ÌýHÌý31P magnetic resonance spectroscopy in the frontal lobeof major depressed patients.ÌýÌýEur Arch Psychiatry Clin Neurosci. 1998;248289-Ìý295
65.Kato
ÌýTMurashita
ÌýJKamiya
ÌýAShioiri
ÌýTKato
ÌýNInubushi
ÌýTÌýDecreased brain intracellular pH measured by 31P-MRS inbipolar disorder: a confirmation in drug-free patients and correlation withwhite matter hyperintensity.ÌýÌýEur Arch Psychiatry Clin Neurosci. 1998;248301-Ìý306
66.Kato
ÌýTKato
ÌýNÌýMitochondrial dysfunction in bipolar disorder.ÌýÌýBipolar Disord. 2000;2180-Ìý190
67.Dager
ÌýSRMarro
ÌýKIMetzger
ÌýGDRichards
ÌýTLÌýPreliminary applications of magnetic resonance spectroscopy to investigatelactate-induced panic.ÌýÌýAm J Psychiatry. 1994;15157-Ìý63
68.Dager
ÌýSRRichards
ÌýTStrauss
ÌýWLArtru
ÌýAÌýSingle-voxel 1H MRS investigation of brain metabolic changesduring lactate-induced panic.ÌýÌýPsychiatry Res. 1997;7689-Ìý99
69.Renshaw
ÌýPFYurgelun-Todd
ÌýDAWei
ÌýHCharles
ÌýHCTohen
ÌýMSharma
ÌýTZipursky
ÌýRBKahn
ÌýRGur
ÌýREGreen
ÌýAJMcEvoy
ÌýJPPerkins
ÌýDOHamer
ÌýRMNemeroff
ÌýCBRothschild
ÌýAJKuldau
ÌýJMStrakowski
ÌýSMTollefson
ÌýGDLieberman
ÌýJAÌýOlanzapine induced reductions in frontal lobe lactate levels correlatewith treatment response in first episode psychosis.ÌýÌýBiol Psychiatry. 2003;53suppl67S
70.Chih
ÌýCLipton
ÌýPRoberts
ÌýELÌýDo active cerebral neurons really use lactate rather than glucose?ÌýÌýTrends Neurosci. 2001;24573-Ìý578
71.Takata
ÌýTSakurai
ÌýTYang
ÌýBYokono
ÌýKOkada
ÌýYÌýEffect of lactate on the synaptic potential, energy metabolism, calciumhomeostasis and extracellular glutamate concentration in the dentate gyrusof the hippocampus from guinea-pig.ÌýÌý±·±ð³Ü°ù´Ç²õ³¦¾±±ð²Ô³¦±ð. 2001;104371-Ìý378
72.Tsacopoulos
ÌýMMagistretti
ÌýPJÌýMetabolic coupling between glia and neurons.ÌýÌýJ Neurosci. 1996;16877-Ìý885
73.Dienel
ÌýGAHertz
ÌýLÌýGlucose and lactate metabolism during brain activation.ÌýÌýJ Neurosci Res. 2001;66824-Ìý838
74.Smith
ÌýDPernet
ÌýAHallett
ÌýWABingham
ÌýEMarsden
ÌýPKAmiel
ÌýSAÌýLactate: a preferred fuel for human brain metabolism in vivo.ÌýÌýJ Cereb Blood Flow Metab. 2003;23658-Ìý664
75.Shulman
ÌýRGHyder
ÌýFRothman
ÌýDLÌýCerebral energetics and the glycogen shunt: neurochemical basis offunctional imaging.ÌýÌýProc Natl Acad Sci U S A. 2001;986417-Ìý6422
76.Clausen
ÌýTZauner
ÌýALevasseur
ÌýJERice
ÌýACBulluck
ÌýRÌýInduced mitochondrial failure in the feline brain: implications forunderstanding acute post-traumatic metabolic events.ÌýÌýBrain Res. 2001;90835-Ìý48
77.Lin
ÌýDDCrawford
ÌýTOBarker
ÌýPBÌýProton MR spectroscopy in the diagnostic evaluation of suspected mitochondrialdisease.ÌýÌýAJNR Am J Neuroradiol. 2003;2433-Ìý41
78.Clark
ÌýJBÌýN-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction.ÌýÌýDev Neurosci. 1998;20271-Ìý276
79.Kato
ÌýTKunugi
ÌýHNanko
ÌýSKato
ÌýNÌýMitochondrial DNA polymorphisms in bipolar disorder.ÌýÌýJ Affect Disord. 2001;62151-Ìý164
80.Calabrese
ÌýVSeapagnini
ÌýGStella
ÌýAM GiuffridaBates
ÌýTEClark
ÌýJBÌýMitochondrial involvement in brain function and dysfunction: relevanceto aging, neurodegenerative disorders and longevity.ÌýÌýNeurochem Res. 2001;26739-Ìý764
81.Nakahara
ÌýIKikuchi
ÌýHTaki
ÌýWNishi
ÌýSKito
ÌýMYonekawa
ÌýYGoto
ÌýYOgata
ÌýNÌýChanges in major phospholipids of mitochondria during postischemicreperfusion in rat brain.ÌýÌýJ Neurosurg. 1992;76244-Ìý250
82.Farber
ÌýSASlack
ÌýBEBlusztan
ÌýJKÌýAcceleration of phospatidylcholine synthesis and breakdown by inhibitorsof mitochondrial function in neuronal cells: a model of the membrane defectof Alzheimer's disease.ÌýÌýFASEB J. 2000;142198-Ìý2206
83.Piccotti
ÌýLMarchetti
ÌýCMigliorati
ÌýGRoberti
ÌýRCorazzi
ÌýLÌýExogenous phospholipids specifically affect transmembrane potentialof brain mitochondria and cytochrome C release.ÌýÌýJ Biol Chem. 2002;27712075-Ìý12081
84.Modica-Napolitano
ÌýJSRenshaw
ÌýPFÌýEthanolamine and phosphoethanolamine inhibit mitochondrial bioenergeticfunction in vitro: implications for mitochondrialdysfunction hypothesis in depression and bipolar disorder.ÌýÌýBiol Psychiatry. 2004;55273-Ìý277
85.Manji
ÌýHKMoore
ÌýGJChen
ÌýGÌýClinical and preclinical evidence for the neurotrophiceffects of mood stabilizers: implications for the pathophysiology and treatmentof manic-depressive illness.ÌýÌýBiol Psychiatry. 2000;48740-Ìý754